Eli Lilly and Company Overview
Pro stress-test →Eli Lilly is a medicine company turning science into healing to make life better for people around the world, having pioneered life-changing discoveries for nearly 150 years and today helping tens of millions of people across the globe. In Q1 2026, worldwide revenue reached $19.8 billion, an increase of 56% compared with Q1 2025, driven by a 65% increase in volume, particularly powered by its blockbuster GLP-1 drugs Mounjaro and Zepbound.
Strategic Profile
Pro stress-test →Lilly commands 60.1% market share of the U.S. obesity and diabetes drug market in Q1 2026, with competitor Novo Nordisk holding 39.4%. The company has generated significant momentum through aggressive dealmaking activity in 2026, completing six M&A deals and spending around $21 billion in total, including the $2.3 billion acquisition of blood cancer specialist Ajax Therapeutics.
Competitive Landscape
Pro stress-test →Lilly maintains commanding 60.1% market share in the U.S. obesity and diabetes drug market, with Novo Nordisk as primary competitor at 39.4% market share. The company competes in immunology, oncology, and neuroscience segments with diversified portfolio and strong late-stage pipeline across multiple therapeutic areas, positioning it to sustain competitive advantages beyond the current GLP-1 cycle.
Industry Context
Eli Lilly and Company operates in Pharmaceutical Manufacturing & Drug Development.
Key facts
Founded: 1876 · Headquarters: Indianapolis, Indiana, US · Employees: 40000+ · Revenue: $82-85B (2026 guidance) · Market cap: $1.9T